Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Akebia Therapeutics (Nasdaq: AKBA) said its executive team will take part in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 9:30 AM EST.

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) said its executive team will take part in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 9:30 AM EST.

A webcast will be available via the company’s Investors site after the conference. The summit runs February 11-12, 2026 in New York City.

Argus Feb 4 session

-2.84% close to close Open Argus

Details

News Market Reaction – AKBA

On Feb 4, the day this news came out, AKBA closed 2.84% below the previous close.

Data tracked by StockTitan Argus for the Feb 4 session.

Market Context

This announcement centers on Akebia’s participation in the Guggenheim Emerging Outlook: Biotech Summ...

Analysis

This announcement centers on Akebia’s participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, offering additional exposure to institutional investors. It follows recent milestones, including establishment of a rare kidney disease pipeline and advancement of Phase 2 programs. Historical news has often been followed by share price weakness despite constructive updates, and recent SEC filings show equity‑based compensation and planned Rule 144 share sales. Investors may watch future clinical readouts and Vafseo revenue trends for more material catalysts.

Key Figures

Summit date range: February 11–12, 2026 Presentation date: February 12, 2026 Presentation time: 9:30 AM EST

Summit date range

February 11–12, 2026

Guggenheim Emerging Outlook: Biotech Summit 2026

Presentation date

February 12, 2026

Akebia executive fireside chat

Presentation time

9:30 AM EST

Scheduled Guggenheim Summit fireside chat

Historical Context

5 past events · Latest: 2026-01-12

5 events

1. 2026-01-12

   Corporate update

   24h Move

   -7.9%

   Outlined Vafseo progress, VOICE/VOCAL timelines, and 2026 pipeline plans.

2. 2026-01-06

   Clinical trial start

   24h Move

   -2.6%

   First patient dosed in Phase 2 praliciguat trial for FSGS.

3. 2026-01-05

   Inducement grants

   24h Move

   -2.6%

   Inducement stock options granted to a new employee under Nasdaq rules.

4. 2025-12-01

   Inducement grants

   24h Move

   -2.6%

   Stock options granted to new hires under inducement award program.

5. 2025-12-01

   Pipeline expansion

   24h Move

   -4.4%

   Announced establishment of rare kidney disease pipeline with AKB‑097 and praliciguat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12 at 9:30 AM EST.

A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.

The Emerging Outlook: Biotech Summit hosted by Guggenheim Securities, LLC, will take place February 11-12, in New York City.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Akebia Therapeutics (AKBA) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?

Akebia will present on Thursday, February 12, 2026 at 9:30 AM EST. According to the company, members of its executive team will participate in a Fireside Chat during the summit's second day.

How can investors watch Akebia Therapeutics (AKBA) Fireside Chat from Guggenheim Biotech Summit 2026?

Investors can view a webcast via the company’s investor website after the event. According to the company, the webcast will be posted in the Investors section at https://ir.akebia.com following the conference.

What is the schedule for the Guggenheim Emerging Outlook: Biotech Summit 2026 where AKBA is speaking?

The summit takes place February 11-12, 2026 in New York City. According to the company, Akebia's participation is scheduled as a Fireside Chat on the morning of February 12.

Who from Akebia Therapeutics will participate in the Guggenheim Biotech Summit 2026 Fireside Chat?

Members of Akebia’s executive team will participate in the Fireside Chat. According to the company, the session features executive-level representation but does not list individual names in the announcement.

Will the Akebia (AKBA) presentation at Guggenheim 2026 be available on demand after the event?

Yes, a webcast will be made available after the conference via the company’s investor site. According to the company, investors can access the recording through the Investors section at https://ir.akebia.com.